Cioteronel Explained

Cioteronel (developmental code name CPC-10997; former tentative brand names Cyoctol, X-Andron) is a nonsteroidal antiandrogen (NSAA) that was never marketed.^{[1] [2] [3]} It was under development between 1989 and 2001 for the topical treatment of androgenetic alopecia (male pattern baldness), and acne and for the oral treatment of benign prostatic hyperplasia; it reached phase III clinical trials for acne and phase II studies for androgenetic alopecia, but was ultimately discontinued due to poor efficacy.^[4]

See also

• Delanterone
• Inocoterone
• Metogest
• Rosterolone
• Topilutamide
• Topterone
• Zanoterone

Notes and References

1. Book: Ganellin CR, Triggle DJ . Dictionary of Pharmacological Agents . 570 . 21 November 1996 . CRC Press . 978-0-412-46630-4 .
2. Book: Lednicer, Daniel . vanc . The Organic Chemistry of Drug Synthesis. 21 November 1994. John Wiley & Sons. 978-0-471-58959-4. 11–.
3. Tiwari A, Krishna NS, Nanda K, Chugh A . Benign prostatic hyperplasia: an insight into current investigational medical therapies . Expert Opinion on Investigational Drugs . 14 . 11 . 1359–72 . November 2005 . 16255676 . 10.1517/13543784.14.11.1359 . 25662071 .
4. Web site: Cioteronel . Adis Insight . Springer Nature Switzerland AG . 2016-11-25 . https://web.archive.org/web/20161229031615/https://adisinsight.springer.com/drugs/800003205 . 2016-12-29 . dead .